NCT01426815View on ClinicalTrials.gov

Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 13, 2012

Primary Completion Date

March 31, 2019

Study Completion Date

March 18, 2019

Conditions
Peripheral Spondylarthritis
Interventions
DRUG

Placebo

The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.

DRUG

Golimumab

The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.

Trial Locations (1)

9000

Ghent University Hospital, Ghent

Sponsors

Collaborators (1)

Janssen Biologics B.V.
All Listed Sponsors
collaborator

Janssen Biologics B.V.

UNKNOWN

lead

University Hospital, Ghent

OTHER